Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gene Therapy Manufacturing Remains Large Hurdle For Development, US FDA's CBER Director Says

Executive Summary

Scale-up in particular is a challenge and FDA wants to help lower the barrier, CBER Director Peter Marks tells rare disease conference.


Related Content

US FDA/NORD Partnership Will Further Increase Patient Involvement In Drug Development
FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan
Gene Therapies: Safety, CMC Draft Guidances Coming From US FDA In 2018
RMAT Designation, Gene Therapies Highlight 2017 CBER Transformation
Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss
Capacity Shortages Unlikely To Hold Back Cell And Gene Therapies
How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts